Market Signal Briefing

, /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Fly-E Group, Inc. ("Fly-E" or the "Company") (NASDAQ: FLYE)have opportunity to lead the securities fraud class action lawsuit.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN FLY-E (FLYE), CLICK HERE BEFORE NOVEMBER 7, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. 

What Is The Lawsuit About?
The complaint filed alleges that, between July 15, 2025 and August 14, 2025, Defendants failed to disclose to investors that: (1) the Defendants continually praised Fly-E's brand reputation in the industry, cost reductions and favorable pricing from suppliers as a key component for Fly-E's ability to grow its sales network, while simultaneously minimizing risks associated with its lithium battery, supply chain changes and the regulatory environment and possible demand fluctuations for its E-Bikes and E-Scooters; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz,
Email us at: [email protected]
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. 

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz,
Telephone: 310-914-5007
Email: [email protected]
Visit our website at: www.frankcruzlaw.com

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

PENSACOLA, Fla.--(BUSINESS WIRE)--A hearing in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Monday, 29 September at 9:00am CT in the United States Courthouse in Pensacola, Florida. The hearing will address oral arguments from the plaintiffs and defendants concerning the issue of pre-emption. The pre-emption defence is common in drug litigation. It involves the drug manufacturer arguing that they cannot be sued for failure to warn under state law, because chang.

, /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Tronox Holdings PLC ("Tronox" or the "Company") (NYSE: TROX).

IF YOU SUFFERED A LOSS ON YOUR TRONOX INVESTMENTS, CLICK HERE BEFORE NOVEMBER 3, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?
The complaint filed alleges that, between February 12, 2025 and July 30, 2025, Defendants failed to disclose to investors that: (1) the Company was ill-equipped to adequately forecast demand for its pigment and zircon products or otherwise minimize the impact of potential demand fluctuations; (2) the Company continued to promote its lofty margin projections which relied upon continually increased sales volumes in its pigment and zircon division; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224) 
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067

Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

SOURCE Glancy Prongay & Murray LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Amazon has reached a historic $2.5bn (£1.9bn) settlement with a US business watchdog over allegations it tricked customers into signing up for Prime membership.

The Federal Trade Commission (FTC) accused the online giant of tricking customers into the membership scheme - which includes perks like faster delivery - and then making it difficult to cancel.

The Seattle-based company will pay $1bn (£750m) in civil penalties, and $1.5bn (£1.1bn) paid back to customers unintentionally enrolled in Prime or deterred from cancelling their subscriptions.

Around 35 million Prime customers will be eligible for a payout from the $1.5bn (£1.1bn) fund, the FTC said.

Customers who signed up for Prime between 23 June, 2019, and 23 June, 2025, through certain offers, and used few Prime benefits afterwards, will automatically receive $51 (£38).

The FTC accused Amazon of making it deliberately difficult for customers to purchase an item without also subscribing to Prime.

It added that customers were, in some cases, presented with a button to complete their transactions, which did not clearly state that it would enrol them into Prime.

Image:
Amazon did not admit any wrongdoing. Pic: Reuters

Getting out of a subscription was often too complicated, and Amazon slowed or rejected changes that would have made cancelling easier, according to an FTC complaint.

The process of unsubscribing, requiring customers to affirm on three pages their desire to quit, was referred to internally as "Iliad", an ancient Greek epic by Homer about the Trojan War, according to the watchdog's complaint.

The settlement came just days after a trial began in Seattle this week.

Chris Mufarrige, director of the Bureau of Consumer Protection, said: "I think it just took a few days for them to see that they were going to lose. And they came to us and they paid out."

Amazon, which admitted no wrongdoing in the case filed two years ago, said it was confident it would win the case but chose to resolve it quickly rather than going through potentially years of trial and appeal.

Image:
Prime benefits include faster delivery. Pic: Reuters

Amazon spokesman, Mark Blafkin, said: "Amazon and our executives have always followed the law and this settlement allows us to move forward and focus on innovating for customers.

"We work incredibly hard to make it clear and simple for customers to both sign up or cancel their Prime membership, and to offer substantial value for our many millions of loyal Prime members around the world."

Under the settlement, Amazon is prohibited from misrepresenting the terms of the subscriptions.

It must fully disclose the costs to be incurred and obtain the customer's express consent for the charge, with a clear option for customers to accept or decline a Prime subscription offered during purchase and avoid language deemed confusing, such as: "No thanks, I don't want free shipping."

Amazon said the settlement does not require it to make any additional changes, only to maintain its current sign-up and cancellation process that it had put in place for a year.

Chipmaker Intel has approached Taiwan Semiconductor Manufacturing Company about investments in manufacturing or partnerships, the Wall Street Journal reported on Thursday, citing people familiar with the matter.

Shares of Coca-Cola Co (NYSE:KO) were last seen down 0.6% to trade at $66.06, after the company was issued a price-target cut from Wells Fargo to $75 from $78. While the beverage name has been struggling of late, the stock is still up 6.1% in 2025, and looks to be within one standard deviation of a historically bullish trendline.

The equity is holding near its 24-month moving average, a trendline it has closed above in 80% of the last 20 months. According to Schaeffer’s Senior Quantitative Analyst Rocky White, this has happened 14 times over the last 20 years, after which the equity was higher one month later 71% of the time, averaging a 4.2% jump. A move of similar magnitude from the stock's current perch would put it above $68.

Options traders are pricing in relatively low volatility expectations, per the shares' Schaeffer's Volatility Index (SVI) of 17%, which ranks in the 14th percentile of readings from the past 12 months.

PALO ALTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has entered into an agreement to make a $150 million Bitcoin (BTC) investment in Datavault AI Inc. (Nasdaq: DVLT, “Datavault”), which is intended to provide growth capital to Datavault to accelerate its supercomputing infrastructure, expand independent data exchanges, and unlock new revenue streams.  

Datavault AI’s patented platform is positioned to capture value across biotech, energy, and entertainment markets, as the global AI market is projected to reach $1.8 trillion by 2030 and the life sciences analytics market was estimated at $35.69 billion in 2024, forecasted to grow at an 11.4% CAGR through 2030. By leveraging Web 3.0, blockchain-secured data trading, and AI-driven analytics, the company delivers secure, scalable solutions addressing trust, data integrity, and monetization challenges.

The strategic investment is intended to capture growth in the biotech data monetization market, which is expected to reach a market size of $30-50 billion by 2024. Scilex intends to leverage its expertise in the biotech and pharmaceutical space to create a potential marketplace for the Real-World Assets (RWA) in the biotech and pharmaceutical industry that are tokenized on a blockchain to represent their ownership in digital form.

Under the terms of the purchase agreement between Datavault and Scilex, Scilex is expected to receive up to an aggregate of 278,914,094 shares of Datavault common stock (at an effective purchase price of $0.5378 per share) ( subject to adjustment for stock splits and similar transactions), with 15,000,000 shares to be issued at the closing of the initial tranche of Scilex’s investment and the remainder to be issued in the second tranche in the form of a pre-funded warrant without beneficial ownership limitations to be issued to Scilex following the approval by Datavault’s stockholders of, among other things, the issuance of Datavault shares to Scilex in excess of 19.99% of Datavault’s total pre-financing shares outstanding. Datavault’s board and management remain unchanged, though Scilex will have the right to nominate two directors to the Company’s board for so long as Scilex maintains beneficial ownership of at least 10% of the Company’s common stock, and the right to nominate one director for so long as Scilex maintains beneficial ownership of at least 5% but no more than 10% of the Company’s common stock.  

Henry Ji, Ph.D., CEO, President and Chairman of the Board of Scilex Holding Company, said, "Datavault's cutting-edge technologies align perfectly with the biotech sector's need for advanced data analytics, AI-driven insights, and super computing power. This investment reflects our belief in Datavault’s ability to transform markets where trust and precision are critical. Biotech is a market we know well, and we will help guide Datavault to maximum revenue generation in our sector while Datavault expands across the global economy. With our resources and their patented technology, we see an incredible opportunity to drive real global impact together.”

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.

https://www.facebook.com/scilex.pharm

https://www.linkedin.com/company/scilex-holding-company/

[email protected]

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California.

About Semnur Pharmaceuticals, Inc.

Semnur is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.

Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, California, and is a majority owned subsidiary of Scilex.

About Datavault AI Inc.

Datavault AI™ (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI's Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI's cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.

The company is headquartered in Beaverton, OR.

Learn more about Datavault AI at www.dvlt.ai

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, Scilex’s proposed investment in Datavault, timing thereof and anticipated use of bitcoin proceeds as growth capital for Datavault’s expansion plans, the market size of the biotech data monetization market, Scilex’s plans to create a potential marketplace for RWA in the biotech and pharmaceutical industry, Scilex’s plans to appoint directors to the Datavault board, potential Datavault stockholder approval,   future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the ability of Scilex and its subsidiaries to achieve the benefits of the transactions contemplated with Datavault, including future financial and operating results; risks related to the outcome of any legal proceedings that may be instituted against the parties regarding the transactions contemplated with Datavault; the risk that the transactions contemplated with Datavault disrupts current plans and operations; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Datavault and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: [email protected]

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB® is a registered trademark owned by Scilex Holding Company.

Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

© 2025 Scilex Holding Company All Rights Reserved.

What a past month it's been for shares of nuclear innovation play Oklo (NASDAQ:OKLO), which are still up close to 88%, even after Wednesday's painful 8% pullback.

, /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LIFEMD, INC. (LFMD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE OCTOBER 27, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?
The complaint filed alleges that, between May 7, 2025 and August 5, 2025, Defendants failed to disclose to investors that: (1) Defendants materially overstated LifeMD's competitive position; (2) Defendants were reckless in raising LifeMD's 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD's RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3 )as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: [email protected],
Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

SOURCE Law Offices of Howard G. Smith

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Key Takeaways Colgate combines pricing actions and productivity moves to expand margins and efficiency.CL leverages AI, analytics and premiumization to optimize portfolio and marketing.Oral Care relaunches and skincare trade-ups drive share gains and brand momentum.
Colgate-Palmolive Company (CL - Free Report) is effectively leveraging its pricing power to support growth and mitigate external cost pressures. The company’s productivity program centers on cost savings and efficiency initiatives designed to strengthen its operational foundation. CL’s pricing strategy includes competitive pricing, value-based tactics and price segmentation to address diverse consumer needs while optimizing value.

Colgate sets prices comparable to its competitors, emphasizing the value and benefits of its products, thereby offering a range of prices to suit different consumer budgets. The company is benefiting from key pricing actions, coupled with its funding-the-growth program and other productivity moves, aimed at driving efficiency and expanding margins.

The company is focused on optimizing the global supply chain for greater agility and resilience, leveraging AI and data analytics to refine portfolio and promotional decisions, and prioritizing investments in high-return areas. By balancing core innovation with premiumization, Colgate is positioning itself to capture growth opportunities and reinforce its leadership in daily-use consumer categories.

Colgate continues to prioritize innovation as a key driver of growth across categories, geographies and price tiers. Management highlighted that premium innovation is fueling momentum, with recent launches such as Colgate Miracle Repair serum, EltaMD UV Skin Recovery, and relaunches of Colgate Total, Sanex, Protex, Suavitel, and Hill’s therapeutic lines. Such initiatives are helping strengthen brand health and expand household penetration by bringing consumer-perceived value at every price point.

In Oral Care, the global relaunch of Colgate Total with a full regimen of toothpaste, toothbrush and mouthwash is delivering incremental share gains, particularly in Latin America and Asia. Beyond Oral Care, Colgate’s skincare brands, including EltaMD and PCA Skin, remain growth engines, supported by consumer trade-ups to premium offerings. The company is also accelerating investment in digital, data, analytics and AI to sharpen its innovation model and optimize marketing execution. Such efforts are likely to continue driving sustained growth and profitability.

CL’s Price Performance, Valuation and EstimatesColgate’s shares have lost 12.5% year to date compared with the industry’s 8.1% dip.

Image Source: Zacks Investment Research

From a valuation standpoint, CL trades at a forward price-to-earnings ratio of 20.99X compared with the industry’s average of 19.09X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for CL’s 2025 and 2026 EPS indicates year-over-year growth of 2.2% and 6.9%, respectively. The company’s EPS estimate for 2025 and 2026 has been stable in the past 30 days.

Image Source: Zacks Investment Research

Colgate currently carries a Zacks Rank #3 (Hold). 

Stocks to Consider in the Consumer Staples Space The Chefs' Warehouse, Inc. (CHEF - Free Report) distributes specialty food and center-of-the-plate products in the United States, the Middle East and Canada. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. 

The Zacks Consensus Estimate for The Chefs' Warehouse’s current financial-year sales and earnings indicates growth of 6.6% and 19.1%, respectively, from the prior-year levels. CHEF delivered a trailing four-quarter earnings surprise of 11.3%, on average.

Celsius Holdings, Inc. (CELH - Free Report) , which is specialized in nutritional functional foods, beverages and dietary supplements, starches and nutrition ingredients, currently sports a Zacks Rank of 1.

The Zacks Consensus Estimate for Celsius’ current financial-year earnings is expected to rise 54.3% from the corresponding year-ago reported figure. CELH delivered a trailing four-quarter earnings surprise of 5.4%, on average.

Post Holdings (POST - Free Report) , which is a consumer-packaged goods holding company, currently carries a Zacks Rank #2 (Buy). POST delivered a trailing four-quarter earnings surprise of 21.4%, on average. 

The Zacks Consensus Estimate for Post Holdings’ current financial-year earnings indicates growth of 11% from the year-ago number. 

CNBC's Julie Sweet joins 'Squawk on the Street' to discuss insights on Accentures latest quarter, how clients are utilizing AI, and much more.

The Company's first location in the state is now accepting patients.

, /PRNewswire/ -- Today, Encompass Health, the nation's largest owner and operator of inpatient rehabilitation hospitals, announced the opening of its first location in the state of Connecticut: Encompass Health Rehabilitation Hospital of Danbury.

Encompass Health Rehabilitation Hospital of Danbury

The 40-bed, 50,500-square-foot freestanding hospital provides essential rehabilitation services that help patients recovering from strokes, brain injuries, spinal cord injuries, amputations and complex orthopedic conditions regain functional ability, independence and quality of life. Patients receive a minimum of three hours of intensive physical, occupational and/or speech therapy five days each week, as well as frequent physician visits and 24-hour nursing care. An interdisciplinary team of highly specialized nurses, therapists and physicians create customized treatment plans to meet each patient's unique recovery goals.

"We're thrilled to bring Encompass Health's high-quality inpatient rehabilitation services to the state of Connecticut," said Mat Gooch, president of Encompass Health's Northeast region. "This hospital will fulfill an important need in the community, enabling patients in the greater Danbury area to recover from serious illnesses and injuries close to their loved ones."

Designed with patients' needs in mind, the hospital will offer amenities such as 40 private patient rooms; a spacious, light-filled therapy gym featuring advanced rehabilitation technologies for every mobility level; an activities of daily living suite with real-world simulated spaces; an in-house dialysis suite; a landscaped therapy courtyard with recreational areas; a dining room; an in-house pharmacy and dayroom areas.

Encompass Health Danbury is Encompass Health's 170th hospital nationwide and its first location in the state of Connecticut.

To learn more, visit encompasshealth.com/locations/danbury-rehab.

About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 170 hospitals in 39 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies™ and Forbes' Most Trusted Companies in America. For more information, visit encompasshealth.com, or follow us on our newsroom, X, Instagram and Facebook.

From Fortune. © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World's Most Admired Companies™ is trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. From Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license.

Encompass Health media contact:
Polly Manuel | 205-970-5912
[email protected]

SOURCE Encompass Health Corp.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Key Takeaways Schwab is considering giving retail investors direct access to private companies.CEO Rick Wurster said growing private firms make expanded access a priority.Robinhood has also filed plans for a fund, giving everyday investors private access.
Charles Schwab (SCHW - Free Report) has been wanting to allow retail investors direct access to private companies. In an interview with Bloomberg Television, as published in an MSN article, SCHW’s CEO and president, Rick Wurster, said that the brokerage giant is exploring ways to permit everyday investors to buy into private companies like fintech giant Stripe and artificial-intelligence firm OpenAI.

Wurster stated, “There’s a lot more private companies today than there used to be, and fewer public companies. It makes sense to think about providing direct access to retail investors to private companies, and that’s something we’re looking at.”

He added, “We would love to see retail investors be able to participate in the growth of private companies in our country.”

Schwab’s latest comments regarding providing broader access to private firms come after the firm announced in April that it will make its new alternative investments platform, Schwab Alternative Investments Select, completely available to all its eligible retail clients who hold household assets worth more than $5 million.

Such efforts have been encouraged of late, as there has been an increasing demand among wealthy clients to tap into private market opportunities in order to meet their portfolio diversification needs.

Schwab’s Competitor Taking Similar StepsEarlier this month, Robinhood Markets (HOOD - Free Report) filed plans with the Securities and Exchange Commission to launch a venture capital fund, Robinhood Ventures Fund I (“RVI”), aimed to provide everyday investors access to private companies before they go public. If approved, the RVI will invest in a small basket of private companies across industries and hold them through IPO and beyond.

Robinhood’s chairman and CEO, Vlad Tenev, said, “For decades, wealthy people and institutions have invested in private companies while retail investors have been unfairly locked out.”

Schwab’s Price Performance & Zacks RankSo far this year, SCHW shares have gained 24.8% compared with the industry’s growth of 30%.

Image Source: Zacks Investment Research

Currently, Schwab carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

A better-ranked brokerage company is Interactive Brokers Group (IBKR - Free Report) . Currently, IBKR carries a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for Interactive Brokers’ 2025 earnings has been revised 1.6% upward over the past 60 days. IBKR shares have gained 45.9% so far this year.

Jabil Inc. (NYSE:JBL) Q4 2025 Earnings Call September 25, 2025 8:30 AM EDT

Company Participants

Adam Berry - Senior Vice President of Investor Relations & Communications
Gregory Hebard - Chief Financial Officer
Steven Borges - Executive Vice President of Global Business Units
Matt Crowley - Executive Vice President of Global Business Units
Andy Priestley - Executive Vice President of Global Business Units
Michael Meheryar Dastoor - CEO & Director
Frederic McCoy - Executive Vice President of Operations
Francis McKay - Senior VP and Chief Supply Chain & Procurement Officer
Mark Mondello - Executive Chairman

Conference Call Participants

Ruplu Bhattacharya - BofA Securities, Research Division
Mark Delaney - Goldman Sachs Group, Inc., Research Division
Steven Fox - Fox Advisors LLC
Melissa Dailey Fairbanks - Raymond James & Associates, Inc., Research Division

Presentation

Operator

Greetings, and welcome to the Jabil Fourth Quarter and Fiscal Year 2025 Financial Results and Investor Briefing. [Operator Instructions] As a reminder, this conference is being recorded. It's now my pleasure to introduce your host, Adam Berry. Please go ahead, sir.

Adam Berry
Senior Vice President of Investor Relations & Communications

Good morning, and welcome to Jabil's Fourth Quarter and Fiscal Year 2025 Earnings Call. This is also Jabil's eighth Annual Investor Briefing. I'm Adam Berry, Senior Vice President of Investor Relations and Corporate Affairs. This is an important day for us at Jabil, and we appreciate your continued interest in our company.

Our investor briefing is always one of the highlights of our calendar. It's our opportunity to step back from the quarter-to-quarter rhythm and give you a deeper look at how we're shaping the business, how we're allocating capital, and how we're positioning Jabil for sustainable long-term growth.

Before we dive in, I need to cover a quick but important point. Some of the information you'll hear during our discussion today will consist of forward-looking statements, including, without limitation, those

Recommended For You

The Investment Committee give you their top stocks to watch for the second half.

CNBC's MacKenzie Sigalos joins 'Money Movers' with the latest news.

Mark Douglas, MNTN CEO, joins 'The Exchange' to discuss a potential concern for advertisers, if advertisers are starting to go elsewhere and much more.

JLL is set to gain from a wide range of products and services and resilient businesses despite macroeconomic woes.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 18, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR) securities between May 6, 2025 and June 19, 2025, inclusive (the “Class Period”).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN KBR, INC. (KBR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On June 19, 2025, KBR’s joint venture, HomeSafe Alliance (“HomeSafe”) announced that it had received a notice from the U.S. Department of Defense’s Transportation Command (TRANSCOM) terminating its multibillion-dollar Household Goods contract “for cause due to [HomeSafe’s] demonstrated inability to fulfill their obligations and deliver high quality moves to Service members.”

On this news, KBR’s stock price fell $3.85, or 7.3%, to close at $48.93 per share on June 20, 2025, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Despite the knowledge that TRANSCOM had, for months, had material concerns with HomeSafe’s ability to fulfill the Global Household Goods Contract, Defendants claimed that the partnership was without issue, and would ramp up in future quarters; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired KBR securities during the Class Period, you may move the Court no later than November 18, 2025 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements.

Contact Us To Participate or Learn More:

If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,

3070 Bristol Pike, Suite 112,

Bensalem, Pennsylvania 19020,

Telephone: (215) 638-4847

Email: [email protected]

Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

More News From Law Offices of Howard G. Smith

HomeIndustriesConstruction/Real EstateJane Street’s stake has provided some respite to Opendoor investors after the stock pulled back sharply over the past couple weeksPublished: Sept. 25, 2025 at 2:44 p.m. ET

Shares of Opendoor Technologies Inc. are rallying on the disclosure that quantitative-trading firm Jane Street Group LLC has amassed a stake in the e-commerce platform for residential-real-estate transactions.

Jane Street’s stake marks the latest chapter in an eventful few months for the heavily shorted Opendoor OPEN, which saw its stock skyrocket amid a retail frenzy that sparked comparisons with earlier meme-stock explosions. The stake, which was revealed in a 13G filing with the Securities and Exchange Commission late Wednesday, could also herald something of a shift in how the stock is perceived.

Partner CenterMost Popular

SAN FRANCISCO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Hagens Berman, a prominent shareholder rights law firm, is probing Coty Inc. (NYSE: COTY), one of the world’s largest beauty companies. The investigation follows a significant 21% drop in Coty's stock price on August 21, 2025, after the company disclosed what it called "retailer inventory destocking issues" alongside its weak Q4 and full-year financial results.

Hagens Berman is looking into whether Coty may have misled investors about its growth trajectory and the success of its digital inventory strategy, known as SAP S/4HANA.

The firm urges investors in Coty who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

Visit: www.hbsslaw.com/investor-fraud/coty
Contact the Firm Now: [email protected]
844-916-0895

Coty Inc. (COTY) Investigation:

Since August 2024, Coty has repeatedly stated that its digital transition “went off without a hitch.” However, the recent disclosures about retailer “destocking”—a term for retailers reducing their excess inventory—appear to be at odds with those earlier, optimistic claims. The investigation is exploring whether Coty may have been deliberately shipping excess inventory to its retail partners to mask its own inventory buildup and meet its earnings expectations, an undisclosed sales practice that would be misleading to investors.

The August 21 earnings report revealed a steep year-over-year revenue decrease in both the Prestige and Consumer Beauty segments, which make up about 65% and 35% of the company's revenue, respectively. The company blamed this weak performance, in part, on the same retailer inventory issues it had previously downplayed. This revelation led to a swift and sharp decline in the stock’s value, which has not recovered.

Hagens Berman’s Investigation on Behalf of Investors

Hagens Berman is now investigating whether Coty and its executives made material misrepresentations that kept investors in the dark about the company’s true financial condition.

“The question for us is whether Coty’s management may have intentionally downplayed the inventory problems to present an overly optimistic picture to the market,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Coty and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the Coty investigation, read more »

Whistleblowers: Persons with non-public information regarding Coty should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Contact:
Reed Kathrein, 844-916-0895

By

PYMNTS
 | 
September 25, 2025

 | 

Apple is asking Europe’s antitrust regulator to do away with its digital protection rule. 

In a blog post Thursday (Sept. 25), the tech giant asked the European Commission (EC) to rethink its Digital Markets Act (DMA) a little more than a year after it was enacted.

“Over that time, it’s become clear that the DMA is leading to a worse experience for Apple users in the EU,” Apple wrote.

“It’s exposing them to new risks, and disrupting the simple, seamless way their Apple products work together. And as new technologies come out, our European users’ Apple products will only fall further behind.”

The landmark DMA was designed to combat market abuse by tech giants operating within the European Union, and covers these companies’ operating systems, app stores and platforms. The law lets regulators levy fines totaling up to 10% of a company’s annual worldwide revenue, or 20% in the case of repeat offenders. 

The EC fined Apple $580 million in April, saying the company had violated rules for allowing developers to direct users to purchases outside of app stores. Apple is appealing the fine.

Advertisement: Scroll to Continue

In its blog post, Apple argued the DMA requirements for permitting other app market places and alternative payment systems don’t take into account the privacy and security standards of the App Store, placing users at risk for being scammed or overcharged.

“The DMA also lets other companies request access to user data and core technologies of Apple products,” the company wrote. “Apple is required to meet almost every request, even if they create serious risks for our users.”

Companies, the blog post added, have required some of the most sensitive data on user’s iPhones, such as messages, emails, medical alerts, or the history of all the Wi-Fi networks a user has joined.

Apple’s comments on the DMA follow a report from earlier this week that regulators in Europe were seeking more information about the company’s financial fraud protections.

Henna Virkkunen, the EU’s executive vice president of tech sovereignty, security and democracy, said the bloc wants to determine whether Apple — along with Meta and Google — is doing enough to prevent fraud.

“We see that more and more criminal actions are taking place online,” said Virkkunen, per a Financial Times report. “We have to make sure that online platforms really take all their efforts to detect and prevent that kind of illegal content.”

That report noted that regulators were set to issue formal requests for information to the three companies, under powers granted under the Digital Services Act (DSA), a sister piece of legislation to the DMA. 

See More In: Apple, Big Tech, Digital Markets Act, DMA, EC, EU, European Commission, European Union, News, privacy, PYMNTS News, regulations, What's Hot

SAN FRANCISCO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- On September 10, 2025, investors in Synopsys, Inc. (NASDAQ: SNPS) saw the price of their shares crater over $216 (-36%) after the company reported its Q3 2025 financial results and revealed significant problems with a major foundry customer.

The development has prompted national shareholders rights firm Hagens Berman to open an investigation into whether Synopsys may have misled investors about its customer risks and growth prospects.

The firm urges investors in Synopsys who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

Visit: www.hbsslaw.com/investor-fraud/snps
Contact the Firm Now: [email protected]
                                     844-916-0895

Synopsys, Inc. (SNPS) Investigation:

In the past Synopsys has assured investors that, while its largest customer (Intel) had reduced its R&D spend, “it does not impact generally the EDA software[]” and downplayed risks based on its “committed, non-cancellable” agreements with Intel involving a mix of EDA software, IP, and hardware.

The company’s assurances may have come into question on September 9, 2025, when Synopsys reported its Q3 2025 financial results and shockingly guided for Q4 2025 GAAP EPS of negative $0.27 to negative $0.16.

During the earnings call, management revealed the company’s underperformance in its IP business and said it was significantly due to “challenges at a major foundry customer” that is “also having a sizeable impact on the year[.]”

This news drove the price of Synopsys shares down 36% the next day, its worst-ever single-day percentage decline since going public in 1992.

“We’re investigating whether Synopsys may have misled investors about risks posed by its high concentration with a single customer,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Synopsys and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the Synopsys investigation, read more »

Whistleblowers: Persons with non-public information regarding Synopsys should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:
Reed Kathrein, 844-916-0895

HomeIndustriesComputers/ElectronicsThe Ratings GameThe Ratings GameIntel reportedly approached Apple about an investment, but absent ‘obvious benefits’ to the smartphone giant, some analysts say the company would be better off just repurchasing more of its own stockPublished: Sept. 25, 2025 at 1:23 p.m. ET

Intel Corp. INTC reportedly has had early-stage talks about a potential investment from Apple Inc. But analysts at Bernstein see a better use for that hypothetical cash.

“Without obvious benefits to Apple … we would far prefer the company to buy back its own shares vs buying [Intel] shares,” Bernstein analysts said in a Thursday note to clients.

Partner CenterMost Popular

HomeIndustriesInternet/Online ServicesTech StocksTech StocksWall Street is slowly coming around to Google’s AI advantages, but one analyst is going so far as to say Alphabet is the ‘best-positioned’ company to dominate in AIPublished: Sept. 25, 2025 at 1:24 p.m. ET

Alphabet Inc. commands a nearly $3 trillion market capitalization, making it the fourth most valuable company in the world — but it’s still a ways behind the market leaders. Nvidia Corp., for instance, is worth $4.36 trillion.

MoffettNathanson analyst Michael Nathanson, however, thinks Alphabet GOOGL GOOG can leapfrog Microsoft Corp. MSFT, Apple Inc. AAPL and Nvidia NVDA to take the No. 1 spot. That would solidify a big turnaround for a company that just a few months ago was in Wall Street’s doghouse due to perceived disadvantages in artificial intelligence.

Partner CenterMost Popular